rs396991 — FCGR3A V158F

Missense variant in Fc gamma receptor IIIa (CD16a) that determines NK cell IgG binding affinity and antibody-dependent cellular cytotoxicity — major pharmacogenomic factor for monoclonal antibody therapy response

See your personal result for FCGR3A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

FCGR3A V158F — The NK Cell Affinity Switch

Your body's natural killer (NK) cells carry a surface receptor called FcgammaRIIIa (CD16a)11 FcgammaRIIIa (CD16a)
The primary Fc receptor on NK cells that binds the constant region of IgG antibodies, triggering antibody-dependent cellular cytotoxicity that connects innate immunity to antibody-mediated defense. This receptor grabs the tail end of IgG antibodies already bound to target cells — infected cells, cancer cells, or cells flagged for destruction — and activates the NK cell to kill. The V158F variant (rs396991) changes a single amino acid in the IgG-binding domain of this receptor, creating two versions with dramatically different binding affinities22 dramatically different binding affinities
The 158V isoform binds IgG1 and IgG3 with approximately 2-fold higher affinity than the 158F isoform. This difference matters both for natural immune surveillance and, critically, for how well monoclonal antibody therapies work.

Genotyping accuracy warning: FCGR3A shares over 98% sequence homology33 over 98% sequence homology
Only four nucleotides differ between FCGR3A and FCGR3B in the genotyped region with its neighboring gene FCGR3B. This extreme similarity can cause consumer genotyping chips and some research assays to inadvertently read FCGR3B sequence instead of FCGR3A, producing incorrect genotype calls. Validated TaqMan assays show 100% accuracy in European and Asian populations but 7.8% error rate in African populations and 1.1% in admixed American populations44 7.8% error rate in African populations and 1.1% in admixed American populations. If your result seems inconsistent with clinical observations, consider confirmatory testing with a gene-specific assay.

The Mechanism

The FCGR3A gene encodes a transmembrane glycoprotein expressed primarily on NK cells, macrophages, and some T-cell subsets. The V158F polymorphism occurs in the second extracellular immunoglobulin-like domain55 second extracellular immunoglobulin-like domain
This domain directly contacts the CH2 region of IgG, and the amino acid at position 158 sits at the binding interface, precisely where IgG makes contact. Valine at position 158 (encoded by the C allele on the plus strand) creates a receptor that binds IgG1 and IgG3 with approximately two-fold higher affinity than phenylalanine at the same position (A allele). This translates directly into enhanced antibody-dependent cellular cytotoxicity (ADCC)66 enhanced antibody-dependent cellular cytotoxicity (ADCC)
ADCC is the process by which NK cells kill antibody-coated target cells; higher receptor affinity means more efficient target recognition and killing.

The functional hierarchy is clear: V/V homozygotes show the strongest ADCC activity, V/F heterozygotes are intermediate, and F/F homozygotes have the weakest response. This gradient affects both natural immune surveillance against infected or abnormal cells and the therapeutic efficacy of monoclonal antibodies that depend on ADCC as their mechanism of action.

The Evidence

Monoclonal Antibody Therapy

The pharmacogenomic significance of V158F was first demonstrated in follicular lymphoma patients treated with rituximab77 follicular lymphoma patients treated with rituximab
Cartron et al. showed V/V patients achieved significantly higher molecular response rates to rituximab monotherapy than V/F or F/F patients. For trastuzumab in HER2-positive breast cancer, a study of Egyptian patients88 study of Egyptian patients
V/V genotype present in 29.6% of responders vs 8.4% of non-responders; median progression-free survival 22 months for V/V vs 6 months for F/F (p=0.003) found V/V carriers had significantly better overall survival and response rates. In follicular lymphoma treated with antibody-chemotherapy combinations99 follicular lymphoma treated with antibody-chemotherapy combinations
SWOG trials showed patients with at least one V allele had better overall survival than F/F patients when treated with antibody-chemotherapy combinations, V allele carriers showed improved outcomes specifically in the antibody-containing treatment arms.

However, results are not universally consistent. A large randomized study in follicular lymphoma1010 A large randomized study in follicular lymphoma
Analysis of 321 patients found no FCGR genotype predicted initial response to rituximab or rituximab-chemotherapy combinations found no predictive value, highlighting that tumor biology, immune microenvironment, and combination chemotherapy may modulate the receptor's influence. The evidence is strongest for rituximab monotherapy and weakens when combined with intensive chemotherapy regimens.

Anti-TNF Therapy in Inflammatory Bowel Disease

In Crohn's disease, V/V carriers showed 100% biological response to infliximab compared to 69.8% of F carriers1111 V/V carriers showed 100% biological response to infliximab compared to 69.8% of F carriers, consistent with enhanced ADCC against TNF-expressing cells. Paradoxically, V/V carriers also show faster infliximab clearance and higher anti-drug antibody rates1212 faster infliximab clearance and higher anti-drug antibody rates
37.5% of V/V patients developed anti-drug antibodies vs 10.6% for V/F and 5% for F/F (OR 6.08) — the same high-affinity receptor that makes the drug work better also accelerates its elimination. This creates a clinical dilemma: V/V patients may respond better initially but need closer therapeutic drug monitoring and potentially dose optimization to maintain response.

Autoimmune Disease Susceptibility

Meta-analyses link V158F to systemic lupus erythematosus susceptibility1313 Meta-analyses link V158F to systemic lupus erythematosus susceptibility
FCGR3A rs396991 shows association with SLE in recessive model (OR 1.26, p = 9.62 x 10-5) and lupus nephritis risk, particularly in non-European populations. The enhanced IgG binding by the V allele may increase immune complex-mediated tissue damage in autoimmune conditions. In rheumatoid arthritis, the association is weaker and may interact with HLA shared epitope status1414 HLA shared epitope status
The V allele may predispose shared epitope-positive individuals to RA.

Practical Implications

The clinical significance of V158F depends heavily on context. For individuals who may receive monoclonal antibody therapy (rituximab for lymphoma, trastuzumab for breast cancer, cetuximab for colorectal cancer), knowing your genotype could inform treatment expectations and potentially guide therapeutic decisions. F/F carriers receiving these therapies may benefit from higher doses, more frequent administration, or combination approaches that don't rely solely on ADCC.

For individuals on anti-TNF therapy (infliximab, adalimumab) for inflammatory bowel disease or rheumatoid arthritis, V/V carriers should be aware of higher anti-drug antibody risk and may benefit from proactive therapeutic drug monitoring rather than reactive testing only when treatment appears to be failing.

For all carriers of the F allele, strategies that support NK cell function take on added importance since the lower-affinity receptor means each NK cell-target interaction is less efficient. While the receptor affinity is genetically fixed, NK cell number and activation state are modifiable.

Interactions

FCGR3A V158F interacts with FCGR2A rs1801274 (H131R)1515 FCGR2A rs1801274 (H131R)
Another Fc gamma receptor polymorphism affecting IgG binding, located on the same chromosome; combined low-affinity genotypes at both loci may compound reduced ADCC. In DLBCL, FCGR2A was the primary driver of survival differences — FCGR3A was not independently associated with DLBCL survival — while FCGR3A showed predictive value in follicular lymphoma settings. In autoimmune disease, the combined effect of low-affinity alleles at both FCGR3A and FCGR2A may influence susceptibility and treatment response to antibody-based therapies. Enhancer SNPs rs4656317 and rs12071048 within FCGR3A are in strong linkage disequilibrium with rs396991 and influence NK cell ADCC through transcriptional regulation of CD16a expression levels, potentially modifying the functional impact of V158F.

Drug Interactions

rituximab reduced_efficacy literature
trastuzumab reduced_efficacy literature
cetuximab reduced_efficacy literature
infliximab dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

AC Intermediate Affinity (F/V) Intermediate

Intermediate NK cell IgG binding — moderate ADCC capacity with mixed pharmacogenomic effects

You carry one copy each of the Phe (F) and Val (V) alleles, producing a mixture of lower-affinity and higher-affinity FcgammaRIIIa receptors on your NK cells. Your ADCC capacity falls between the two homozygous states. About 41% of the global population shares this genotype, making it the most common. For monoclonal antibody therapy, heterozygotes typically show intermediate response rates. For anti-TNF therapy, your anti-drug antibody risk is moderate (about 10.6% compared to 5% for F/F and 37.5% for V/V).

AA Low Affinity (F/F) Reduced

Reduced NK cell IgG binding and ADCC — lower monoclonal antibody therapy response but slower drug clearance

The F/F genotype produces the lowest-affinity form of FcgammaRIIIa (CD16a) on your NK cells and macrophages. Functional studies show approximately 2-fold lower IgG binding compared to V/V homozygotes. In the context of rituximab therapy for lymphoma, F/F carriers showed lower molecular response rates in the original Cartron et al. study. For trastuzumab in HER2-positive breast cancer, F/F carriers had median progression-free survival of 6 months compared to 22 months for V/V carriers, and 56.3% of progressive disease cases were F/F.

However, F/F carriers have a potential advantage with anti-TNF therapy: lower anti-drug antibody formation rates (only 5% vs 37.5% for V/V), meaning more stable long-term drug levels and potentially more sustained treatment response. The lower receptor affinity means less Fc-mediated clearance of therapeutic antibodies.

CC High Affinity (V/V) High

Enhanced NK cell IgG binding and ADCC — best monoclonal antibody response but faster drug clearance and higher autoimmune risk

The V/V genotype produces the highest-affinity form of FcgammaRIIIa on all your NK cells and macrophages. The two-fold increase in IgG binding over F/F translates into meaningfully enhanced ADCC in clinical settings. In trastuzumab-treated breast cancer, V/V carriers achieved 22-month median progression-free survival versus 6 months for F/F (p=0.003), and 35.5% of complete responders carried V/V versus only 8.4% of non-responders.

The trade-off appears with anti-TNF therapy: V/V carriers clear infliximab 16% faster and develop anti-drug antibodies at 6-fold higher rates (OR 6.08). This means V/V carriers may initially respond better to anti-TNF therapy but are more likely to lose response over time without proactive drug monitoring and dose optimization. The enhanced immune complex clearance also contributes to slightly elevated susceptibility to certain autoimmune conditions, particularly systemic lupus erythematosus and lupus nephritis.